- Trials with a EudraCT protocol (93)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
93 result(s) found for: Malignant Mesothelioma AND Cancer.
Displaying page 1 of 5.
EudraCT Number: 2004-002537-39 | Sponsor Protocol Number: H3E-IT-S079 | Start Date*: 2005-04-04 | |||||||||||
Sponsor Name:ELI LILLY | |||||||||||||
Full Title: Phase II Trial of Neoadjuvant ALIMTA plus Cisplatin followed by Surgery and Radiation in the Treatment of Pleural Mesothelioma | |||||||||||||
Medical condition: Plaural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014293-17 | Sponsor Protocol Number: AGO/2009/006 | Start Date*: 2009-09-10 | |||||||||||
Sponsor Name:University Hospital Ghent | |||||||||||||
Full Title: Phase II study of cetuximab combined with cisplatin or carboplatin/pemetrexed as first line treatment in patients with malignant pleural mesothelioma. | |||||||||||||
Medical condition: Patients with malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004433-26 | Sponsor Protocol Number: 3638 | Start Date*: 2016-05-04 | |||||||||||||||||||||
Sponsor Name:North Bristol NHS Trust | |||||||||||||||||||||||
Full Title: Zoledronic acid in the management of malignant pleural mesothelioma - a feasibility study | |||||||||||||||||||||||
Medical condition: Malignant pleural mesothelioma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002876-10 | Sponsor Protocol Number: ONC-2014-002 | Start Date*: 2014-10-31 | |||||||||||
Sponsor Name:Istituto Clinico Humanitas | |||||||||||||
Full Title: A PHASE II STUDY OF THE COMBINATION OF GEMCITABINE AND IMATINIB MESYLATE IN PEMETREXED-PRETREATED PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA | |||||||||||||
Medical condition: Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001139-10 | Sponsor Protocol Number: EZH-203 | Start Date*: 2016-06-27 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Epizyme, Inc. | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with Relapsed or Refractory BAP1 deficientMalignant Mesothelioma | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Part 1 – Subjects with relapsed or refractory malignant mesothelioma regardless of BAP1 status Part 2 – Subjects with relapsed or refractory BAP1-deficient malignant mesothelioma | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-001016-11 | Sponsor Protocol Number: SAKK17/16 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:SAKK | |||||||||||||
Full Title: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial | |||||||||||||
Medical condition: Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005894-77 | Sponsor Protocol Number: 107/2007/O/Sper | Start Date*: 2007-12-18 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study) | |||||||||||||
Medical condition: malignant pleural mesothelioma (MPM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000949-11 | Sponsor Protocol Number: 0683-014 | Start Date*: 2005-07-06 | |||||||||||
Sponsor Name:Merck Sharp & Dohme (Sweden) AB | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated Wit... | |||||||||||||
Medical condition: Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) BE (Prematurely Ended) PT (Prematurely Ended) IT (Prematurely Ended) GR (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003830-34 | Sponsor Protocol Number: 415-13 | Start Date*: 2014-05-15 | |||||||||||
Sponsor Name:Asklepios Fachkliniken München Gauting | |||||||||||||
Full Title: Pleurectomy/decortication and hypterthermic intrathoracic chemotherapy compared to pleurectomy/decortication in patients with malignant pleural mesothelioma | |||||||||||||
Medical condition: malignant pleuramesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002721-30 | Sponsor Protocol Number: NIPU | Start Date*: 2021-01-14 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) | |||||||||||||
Medical condition: Malignant pleural mesothelioma (MPM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005201-48 | Sponsor Protocol Number: 1199.93 | Start Date*: 2013-07-16 | |||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||
Full Title: LUME-Meso: Double blind, randomised, multicentre, phase II/III study of nintedanib in combination with pemetrexed / cisplatin followed by continuing nintedanib monotherapy versus placebo in combina... | |||||||||||||
Medical condition: Unresectable Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) GB (Completed) FR (Completed) DK (Completed) ES (Prematurely Ended) BE (Completed) NL (Prematurely Ended) SE (Completed) PT (Completed) CZ (Completed) AT (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000009-51 | Sponsor Protocol Number: 08052 | Start Date*: 2007-01-22 | |||||||||||
Sponsor Name:EORTC-European Organisation for the Research and Treatment of Cancer | |||||||||||||
Full Title: Phase II study of Bortezomib (VELCADE) with cisplatin as first line treatment of malignant mesothelioma | |||||||||||||
Medical condition: Malignant mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) IT (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002560-28 | Sponsor Protocol Number: N19PEM | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:NKI-AVL | |||||||||||||
Full Title: PEMbrolizumab Plus Lenvatinib In Second Line And Third Line Malignant Pleural MEsotheLiomA Patients. | |||||||||||||
Medical condition: unresectable malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000445-19 | Sponsor Protocol Number: SAKK 17/04 | Start Date*: 2007-07-27 | |||||||||||
Sponsor Name:Swiss group for clinical cancer research | |||||||||||||
Full Title: Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial | |||||||||||||
Medical condition: Patients with pleural mesothelioma, T<=3, N<=2, M0 (IMIG-system) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004727-23 | Sponsor Protocol Number: 3850 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:North Bristol NHS Trust Research & Innovation | |||||||||||||
Full Title: A Trial of Intra-pleuraL OK-432 Therapy in mesothelioma (TILT): A feasibility study using the ‘trial within a cohort’ methodology | |||||||||||||
Medical condition: Malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001992-30 | Sponsor Protocol Number: | Start Date*: 2015-04-20 | |||||||||||
Sponsor Name:University of Leicester | |||||||||||||
Full Title: A randomised controlled phase II trial of oral vinorelbine as second line therapy for patients with malignant pleural mesothelioma | |||||||||||||
Medical condition: Histologically confirmed malignant pleural mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024496-37 | Sponsor Protocol Number: 1716-12 | Start Date*: 2012-05-04 | |||||||||||
Sponsor Name:Virttu Biologics Limited | |||||||||||||
Full Title: A PHASE I/IIa STUDY OF THE SAFETY, TOLERABILITY AND BIOLOGICAL EFFECT OF SINGLE AND REPEAT ADMINISTRATION OF THE SELECTIVELY REPLICATION-COMPETENT HERPES SIMPLEX VIRUS HSV1716 INTO THE TUMOUR-BEAR... | |||||||||||||
Medical condition: Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003935-20 | Sponsor Protocol Number: N14MPN | Start Date*: 2015-07-02 | |||||||||||
Sponsor Name:Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | |||||||||||||
Full Title: A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study | |||||||||||||
Medical condition: A single arm phase II study of Nivolumab in patients with progressive malignant pleural mesothelioma: interim biopsy analysis to determine efficacy. Acronym: NivoMes Study | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003169-82 | Sponsor Protocol Number: rAd-IFN-MM-301 | Start Date*: 2019-01-30 | |||||||||||
Sponsor Name:Trizell Ltd | |||||||||||||
Full Title: A Phase III, Open Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in Combination wit... | |||||||||||||
Medical condition: Malignant Pleural Mesothelioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) FR (Ongoing) PL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003762-39 | Sponsor Protocol Number: GOIRC–03-2019 | Start Date*: 2021-03-09 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION | |||||||||||||
Medical condition: MALIGNANT PLEURAL MESOTHELIOMA PATIENTS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.